Sleep Quality and Congestion with Breathe Right Nasal Strips: Two Randomized Controlled Trials

Michael J Noss, Renee Ciesla, Gilbert Shanga, Michael J Noss, Renee Ciesla, Gilbert Shanga

Abstract

Introduction: Two multicenter, double-blind, randomized controlled trials assessed the effect of Breathe Right Nasal Strips (BRNS) on sleep-related quality of life in otherwise healthy subjects with chronic nocturnal nasal congestion who reported trouble sleeping.

Methods: Subjects were randomized to BRNS or a placebo strip for approximately 8 h each night for 14 days. Efficacy was assessed in the clinic using the Nocturnal Rhinoconjunctivitis Quality of Life Questionnaire (NRQLQ).

Results: A total of 140 subjects were randomized in Study 1, and 130 in Study 2. There was no significant difference between BRNS and placebo on either the NRQLQ "Sleep Problems" domain or the "Feel Tired and Unrefreshed" item of the "Symptoms on Waking in the Morning" domain at day 7 or 14. There was, however, a significant change in the least squares mean difference from baseline to days 7 and 14 in both the BRNS and placebo arms for each of these endpoints. BRNS were well tolerated.

Conclusions: BRNS did not significantly improve subjective measures of sleep quality and nasal congestion compared with placebo strips in this population of chronic nocturnal congestion sufferers with self-reported sleep impairment, possibly due to a strong placebo effect.

Funding: GlaxoSmithKline Consumer Healthcare. CLINICALTRIALS.

Gov registration numbers: Study 1: NCT03549117; Study 2: NCT03549130.

Keywords: Quality of life; Randomized controlled trial; Respiratory; Rhinitis; Sleep.

Figures

Fig. 1
Fig. 1
Subject dispositions. Study 1 (a); Study 2 (b). BRNS Breathe Right Nasal Strip
Fig. 2
Fig. 2
Least square mean (95% CI) change from baseline on the “Sleep Problems” domain of the NRQLQ for Study 1 (a) and Study 2 (b), ITT populations. CI confidence interval, ITT intent-to-treat, LS least square, NRQLQ Nocturnal Rhinoconjunctivitis Quality of Life Questionnaire
Fig. 3
Fig. 3
Least square mean (95% CI) change from baseline on the “Feel Tired and Unrefreshed” item of the “Symptoms on Waking in the Morning” domain of the NRQLQ for Study 1 (a) and Study 2 (b), ITT populations. CI confidence interval, ITT intent-to-treat, LS least square, NRQLQ Nocturnal Rhinoconjunctivitis Quality of Life Questionnaire

References

    1. Storms W. Allergic rhinitis-induced nasal congestion: its impact on sleep quality. Prim Care Respir J. 2008;17(1):7–18. doi: 10.3132/pcrj.2008.00001.
    1. Stull DE, Roberts L, Frank L, Heithoff K. Relationship of nasal congestion with sleep, mood, and productivity. Curr Med Res Opin. 2007;23(4):811–819. doi: 10.1185/030079907X178793.
    1. Gehring JM, Garlick SR, Wheatley JR, Amis TC. Nasal resistance and flow resistive work of nasal breathing during exercise: effects of a nasal dilator strip. J Appl Physiol (1985) 2000;89(3):1114–1122. doi: 10.1152/jappl.2000.89.3.1114.
    1. Wong LS, Johnson AT. Decrease of resistance to air flow with nasal strips as measured with the airflow perturbation device. Biomed Eng Online. 2004;3(1):38. doi: 10.1186/1475-925X-3-38.
    1. Di Somma EM, West SN, Wheatley JR, Amis TC. Nasal dilator strips increase maximum inspiratory flow via nasal wall stabilization. Laryngoscope. 1999;109(5):780–784. doi: 10.1097/00005537-199905000-00018.
    1. Gosepath J, Mann WJ, Amedee RG. Effects of the Breathe Right nasal strips on nasal ventilation. Am J Rhinol. 1997;11(5):399–402. doi: 10.2500/105065897781285990.
    1. Seto-Poon M, Amis TC, Kirkness JP, Wheatley JR. Nasal dilator strips delay the onset of oral route breathing during exercise. Can J Appl Physiol. 1999;24(6):538–547. doi: 10.1139/h99-035.
    1. Latte J, Taverner D. Opening the nasal valve with external dilators reduces congestive symptoms in normal subjects. Am J Rhinol. 2005;19(2):215–219. doi: 10.1177/194589240501900217.
    1. Hoyvoll LR, Lunde K, Li HS, Dahle S, Wentzel-Larsen T, Steinsvag SK. Effects of an external nasal dilator strip (ENDS) compared to xylometazolin nasal spray. Eur Arch Otorhinolaryngol. 2007;264(11):1289–1294. doi: 10.1007/s00405-007-0345-6.
    1. Griffin JW, Hunter G, Ferguson D, Sillers MJ. Physiologic effects of an external nasal dilator. Laryngoscope. 1997;107(9):1235–1238. doi: 10.1097/00005537-199709000-00014.
    1. Roithmann R, Chapnik J, Cole P, Szalai J, Zamel N. Role of the external nasal dilator in the management of nasal obstruction. Laryngoscope. 1998;108(5):712–715. doi: 10.1097/00005537-199805000-00016.
    1. Burres SA. Acoustic rhinometry of the oriental nose. Am J Rhinol. 1999;13(5):407–410. doi: 10.2500/105065899781367519.
    1. Gosepath J, Amedee RG, Romantschuck S, Mann WJ. Breathe Right nasal strips and the respiratory disturbance index in sleep related breathing disorders. Am J Rhinol. 1999;13(5):385–389. doi: 10.2500/105065899781367456.
    1. Pevernagie D, Hamans E, Van Cauwenberge P, Pauwels R. External nasal dilation reduces snoring in chronic rhinitis patients: a randomized controlled trial. Eur Respir J. 2000;15(6):996–1000. doi: 10.1034/j.1399-3003.2000.01504.x.
    1. Ulfberg J, Fenton G. Effect of Breathe Right nasal strip on snoring. Rhinology. 1997;35(2):50–52.
    1. Scharf MB, Brannen DE, McDannold M. A subjective evaluation of a nasal dilator on sleep & snoring. Ear Nose Throat J. 1994;73(6):395–401.
    1. Camacho M, Malu OO, Kram YA, Nigam G, Riaz M, Song SA, et al. Nasal dilators (Breathe Right strips and NoZovent) for snoring and OSA: a systematic review and meta-analysis. Pulm Med. 2016;2016:4841310. doi: 10.1155/2016/4841310.
    1. Juniper EF, Rohrbaugh T, Meltzer EO. A questionnaire to measure quality of life in adults with nocturnal allergic rhinoconjunctivitis. J Allergy Clin Immunol. 2003;111(3):484–490. doi: 10.1067/mai.2003.137.
    1. del Cuvillo A, Sastre J, Bartra J, Mullol J, DaVila I, Montoro J, et al. Placebo effect in clinical trials involving patients with allergic rhinitis. J Investig Allergol Clin Immunol. 2011;21(Suppl 3):40–45.
    1. Van Cauwenberge P, Juniper EF. Comparison of the efficacy, safety and quality of life provided by fexofenadine hydrochloride 120 mg, loratadine 10 mg and placebo administered once daily for the treatment of seasonal allergic rhinitis. Clin Exp Allergy. 2000;30(6):891–899. doi: 10.1046/j.1365-2222.2000.00914.x.
    1. Cohen BM. Clinical correlants of changes in nasal flow/resistance (Rn) measurements. Allergol Immunopathol (Madr). 1978;6(3):217–223.
    1. Doddi NM, Eccles R. The relationship between nasal index and nasal airway resistance, and response to a topical decongestant. Rhinology. 2011;49(5):583–586.
    1. Allocca G, Ma S, Martelli D, Cerri M, Del Vecchio F, Bastianini S, et al. Validation of ‘Somnivore’, a machine learning algorithm for automated scoring and analysis of polysomnography data. Front Neurosci. 2019;13:207. doi: 10.3389/fnins.2019.00207.

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi